Pisa at the top in Tuscany and Italy
An alternative way to hospitalization, to defeat Covid, exists. And it is also the only one of the “non-vaccine” therapies so much heralded by the so-called no vax. Dr. Marco Falcone, director in pectore of the Aoup Infectious Diseases Operative Unit (awaiting the official appointment of the successor of Professor Francesco Menichetti, who has retired for a few days): “The mainly monoclonal represent in this moment thethe only winning therapy against the Coronavirus. There are no others. There are two ways in front of this scourge: the vaccine, to prevent contagion and the development of severe symptoms; or the illness. The positives may heal spontaneously, thanks to their immune system, or they may need more important support: hospitalization or resorting to monoclonal therapy. Other solutions, in the current state of things, do not exist “.
And precisely in the administration of monoclonals, from the start of the campaign to March 2021, Pisa stood out as one of the most active provinces in Tuscany and throughout Italy. This is confirmed by the data collected in close collaboration by the hospital and by the general practitioners of the North West Tuscany ASL: all of them were about 400 people treated with this therapy. “In many cases, Dr. Falcone points out – individuals who, otherwise, could run the risk of developing serious symptoms, will also be born for their lives have been treated in a timely manner”. The province of Pisa joins those of Florence and Arezzo in the list of territories where monoclonals have been applied with more frequency and success: Tuscany represents over 17% of the total monoclonals administered, and with Veneto and Lazio contributes to 60% of the national total.
“A fact that certifies the virtuous circle built in tandem by the Aoup specialists and the general practitioner network – Stresses proudly Luca Puccetti, provincial secretary Fimmg – the protocol in fact requires the doctor to report when a patient presents the swab. The patient can choose whether to join the therapy or not. In the first case, it comes taken over within 72 hours by the hospital system for the administration of monoclonal individuals. “The latter a two macrofamilies: one approved by Aifa, another developed through one research study by the Pisan university hospital.
The monoclonals approved by the national regulatory body are those produced by Eli Lilly And Regeneron Roche, those administered as part of the Aoup study are produced by Astrazeneca and Tls, the company based in Siena. “The monoclonals approved by Aifa are generally administered to frail patients or patients with more severe symptoms – explain Puccetti and Falcone – the others instead go to people who do not have serious problems”. Monoclonal therapy represents “the most valid tool for avoid hospitalization – concludes the director of Infectious Diseases – with positive effects also on the load that the structure has to manage. By the end of the year, the oral antivirals, which can be administered directly by general practitioners. An additional very important ally in the fight against Covid “.